Thrive Capital Management (Pennsylvania)’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.93M | Buy |
15,377
+11,175
| +266% | +$1.4M | 0.61% | 72 |
|
|
2025
Q1 | $465K | Sell |
4,202
-6,974
| -62% | -$771K | 0.28% | 84 |
|
|
2024
Q4 | $1.53M | Buy |
11,176
+7,121
| +176% | +$972K | 0.7% | 62 |
|
|
2024
Q3 | $467K | Buy |
4,055
+77
| +2% | +$8.87K | 0.22% | 128 |
|
|
2024
Q2 | $548K | Buy |
3,978
+2,225
| +127% | +$306K | 0.25% | 110 |
|
|
2024
Q1 | $242K | Buy |
+1,753
| New | +$242K | 0.13% | 102 |
|